ROBERT A. GORDON, M.D.; JOHN W. BURNSIDE, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
D-penicillamine is used for the treatment of active rheumatoid arthritis, Wilson's Disease, and cystinuria. It has been reported to be implicated as a cause of autoimmune diseases and serologic autoantibodies. Clinical pictures indistinguishable from lupus erythematosus (1), Goodpasture's syndrome (2), and polymyositis (3) have been reported as complications of D-penicillamine therapy. A reversible form of myasthenia gravis has been reported in England to be associated with the use of D-penicillamine for the treatment of severe rheumatoid arthritis (4) and Wilson's Disease (5). This report describes the case of a patient who developed myasthenia gravis while being treated with D-penicillamine for
GORDON RA, BURNSIDE JW. D-Penicillamine-Induced Myasthenia Gravis in Rheumatoid Arthritis. Ann Intern Med. 1977;87:578–579. doi: 10.7326/0003-4819-87-5-578
Download citation file:
Published: Ann Intern Med. 1977;87(5):578-579.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use